News & Views

10 March 2014

New blood test predicts Alzheimer's, dementia

Researchers have developed a new blood test that can predict with 90% accuracy whether a healthy person will develop Alzheimer's or cognitive decline within 3 years. They report how they identified and validated the 10 biomarkers that form the basis of the test in a study published in Nature Medicine.

Study leader Howard J. Federoff, a professor of neurology at Georgetown University Medical Center in Washington, DC, says:

"Our novel blood test offers the potential to identify people at risk for progressive cognitive decline and can change how patients, their families and treating physicians plan for and manage the disorder."

Rates of Alzheimer's disease - a condition that gradually clogs up and kills brain cells and leads to memory loss and mental decline - are rising rapidly around the globe. The disease mostly affects older people, although there are rare forms that can start earlier in life.

In 2010, there were 35 million people with Alzheimer's disease worldwide. The World Health Organization (WHO) predicts this number will double every 20 years, rising to 115 million by 2050.

Ability to detect Alzheimer's in preclinical stages is key

There are currently no treatments that cure or halt the disease, something scientists believe could be due to our inability to detect it before it has progressed to the point where clinical symptoms emerge.

Prof. Federoff explains that while there have been many attempts to produce drugs that slow or reverse Alzheimer's, they have all failed, and one reason could be because the drugs are tested at too late a stage of the disease.

Therefore, he and his colleagues focused on the preclinical stage of the disease, looking for biomarkers or telltale molecules that begin circulating in the blood before the disease takes hold.

Every year for 5 years, the researchers tested memory and mental skills, and blood samples of over 500 participants over the age of 70.

They then took the data of 53 participants who developed Alzheimer's or mild cognitive impairment (MCI) and compared it with 53 who remained cognitively healthy. They used mass spectrometry to analyze the blood samples. This method is used to pinpoint the unique chemical signature of molecules.

Panel of 10 blood biomarkers predicted Alzheimer's, MCI with 90% accuracy

They found 10 phospholipids - a type of fat that forms a major component of cell membranes - were present at consistently lower levels in blood samples of most of the group that developed Alzheimer's or MCI. They validated their results in another group of 41 participants.

Prof. Federoff says:

"The lipid panel was able to distinguish with 90% accuracy these two distinct groups - cognitively normal participants who would progress to MCI or AD within 2 to 3 years, and those who would remain normal in the near future."

The researchers believe the 10 biomarkers in the panel they selected show signs of changes that occur when the membranes of brain cells begin to break down. Two of them have already been linked to Alzheimer's.

They consider their findings represent a major step forward in producing a biomarker test that could be used for large-scale screening to find people at risk of Alzheimer's or MCI.

Prof. Federoff explains their findings in the video below:

Questions still remain, further tests needed

Though this is a potential breakthrough in diagnosing Alzheimer's, it is still an incurable disease, which leaves an ethical question about whether or not patients would benefit from knowing in advance that they will develop an incurable condition.

Additionally, the 90% accuracy rate still leaves 10% open to question. NBC News reported that there were no "false negatives" in the blood test and quoted Prof. Federoff as saying, "We did not find any individual that didn't test positive that became demented." So, could 10% of patients receive a false positive?

Prof. Federoff says independent labs now need to do larger studies, over longer periods, looking at different age groups and a more diverse racial mix, to confirm their findings, adding that:

"We're intending to design a clinical trial where we'll use this panel to identify people at high risk for Alzheimer's to test a therapeutic agent that might delay or prevent the emergence of the disease."

The National Institutes of Health and the Department of Defense funded the study.

Meanwhile, Medical News Today recently reported another study by researchers in the US and Australia, which found some Alzheimer's biomarkers decrease as symptoms emerge. They showed that spinal fluid concentrations of three biomarkers proposed for Alzheimer's are higher during the preclinical stage of the disease. The information could be very important for clinical trials of drugs to treat or prevent the disease.

Written by Catharine Paddock PhD


The information on this site is intended only for the use of Independent Financial Advisors (IFAs) and other professionally recognised financial intermediaries & institutions.. Should you proceed to access this site, you will be representing and warranting that you are an IFA or other professionally recognised financial intermediary . What follows is not an offer or invitation to acquire an investment and should therefore not be relied upon by, any person in any jurisdiction where such an offer or invitation would be unlawful. Persons in respect of whom such prohibitions apply must not access this web site. None of the information contained on this site constitutes personal recommendations nor advice. Product details should always be read in conjunction with the appropriate offering documents. An application for any of the investment products on this page should be made having fully read not only the relevant application form, but also the relevant terms and conditions and offering documents. If you are unsure about the meaning of any information provided on this web page, then please consult your financial or other professional adviser. We do not offer investment advice.

This web site may contain or be linked to advice or statements of third parties. We make no representation as to the accuracy, completeness, timeliness or suitability of such information, and we have not and will not review or update such information and caution you that any use made of such information is at your own risk. Some of the information contained on this web site may also have been prepared or provided by third parties and may not have been verified by us. We hereby exclude any liability arising out of any preparation or provision of such information for the web site and makes no warranty as to the accuracy, suitability or completeness of any such information.

I agree, Continue

Information on this webpage relates to and is provided by Montreux Capital Management (UK) Limited

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Montreux Capital Management (UK) Limited and Sapia Partners LLP (together "the Sponsors," or "Sponsor) do not provide specific individual advice on the suitability of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.

Montreux Capital Management (UK) Limited is an Appointed Representative of Sapia Partners LLP which is authorised and regulated by the Financial Conduct Authority.

I agree, Continue